The Pro Medicus Ltd (ASX: PME) share price could be on the move after the healthcare technology company announced a new 5-year, $28 million contract renewal with Allegheny Health Network and additional workflow integration.
What did Pro Medicus report?
- Signed a 5-year, A$28 million contract renewal with Allegheny Health Network (AHN)
- Contract includes the addition of Visage 7 Workflow with AHN
- Renewal features increased minimums and higher fee per transaction
- Brings total contract renewals for FY26 to A$125 million
- Ongoing transaction-based model with potential upside
What else do investors need to know?
Pro Medicus has maintained a strong relationship with AHN, one of the largest health networks in the Pittsburgh region, for over a decade. The inclusion of Visage 7 Workflow marks an expansion of the existing partnership, reflecting increasing demand for the company’s clinical imaging solutions.
The contract continues Pro Medicus’ international momentum, following consistent client retention and renewals throughout the financial year. The transaction-based model may offer further upside if imaging volumes increase.
What’s next for Pro Medicus?
Pro Medicus plans to continue expanding in the North American market, leveraging its Visage 7 platform and end-to-end imaging solutions. The company is focused on client retention and attracting new health networks, aiming to boost both financial and clinical impact.
Investor attention will likely remain on contract wins and recurring revenue growth, as Pro Medicus builds on its track record of renewals and long-term partnerships.
Pro Medicus share price snapshot
Over the past 12 months, the Pro Medicus shares have declined 53%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
The post Pro Medicus renews $28m contract with Allegheny Health Network appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Lendlease reports $250m MSG North sale and FY26 loss
- Ventia secures $133m contract extension at Australian Marine Complex
- These were the worst-performing ASX 200 shares in May
- 5 things to watch on the ASX 200 on Monday
- Why did ASX 200 retail shares lead the market last week?
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.